FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2399742010> ?p ?o ?g. }

• W2399742010 endingPage "948" @default.
• W2399742010 startingPage "948" @default.
• W2399742010 abstract "<h3>Importance</h3> Patients with<i>EGFR</i>-mutant lung cancer benefit from treatment with EGFR inhibitors such as erlotinib, gefitinib, and afatinib, but outcomes are limited by the eventual development of resistance to these agents. Over half of patients acquire a secondary T790M mutation in<i>EGFR</i>at the time of progression and a substantial minority develops resistance through other mechanisms. Multiple treatment strategies are now available to patients whose disease has progressed on their initial EGFR inhibitor, including therapies targeting both T790M, and non–T790M-mediated resistance. <h3>Observations</h3> This review summarizes information about and current treatment strategies for patients with<i>EGFR</i>-mutant lung cancer whose disease progresses on their initial EGFR inhibitor, including those with T790M and other types of acquired resistance. Postprogression therapy should be tailored based on identified resistance mechanisms, sites, and pace of disease progression, and patient preference. Biopsy and genotyping of resistant tissue or plasma are essential to identifying resistance mechanisms and selecting the most appropriate treatment when patients’ disease progresses during treatment with an initial EGFR inhibitor. Third-generation EGFR inhibitors are generally preferred for patients with T790M-positive resistance, whereas standard chemotherapy and clinical trials are preferred for those without T790M. For select patients, treatment can be continued beyond progression and local ablative therapies can be used to target sites of oligoprogression. <h3>Conclusions and Relevance</h3> Treatment for patients who progress on their initial EGFR inhibitor should be tailored to identified resistance mechanisms and sites of progression. Emerging reports about resistance to third-generation EGFR inhibitors will lay the groundwork for overcoming the next generation of resistance, and further research is needed to develop more effective therapies." @default.
• W2399742010 created "2016-06-24" @default.
• W2399742010 creator A5069070706 @default.
• W2399742010 creator A5075333926 @default.
• W2399742010 date "2016-07-01" @default.
• W2399742010 modified "2023-09-27" @default.
• W2399742010 title "Treatment of<i>EGFR</i>-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors" @default.
• W2399742010 cites W1189434757 @default.
• W2399742010 cites W1516645741 @default.
• W2399742010 cites W1546552389 @default.
• W2399742010 cites W1584059175 @default.
• W2399742010 cites W1904060183 @default.
• W2399742010 cites W1908940658 @default.
• W2399742010 cites W1980497534 @default.
• W2399742010 cites W1997360163 @default.
• W2399742010 cites W1998971866 @default.
• W2399742010 cites W1999896690 @default.
• W2399742010 cites W2002937040 @default.
• W2399742010 cites W2030227571 @default.
• W2399742010 cites W2033074912 @default.
• W2399742010 cites W2043696829 @default.
• W2399742010 cites W2049553585 @default.
• W2399742010 cites W2055309515 @default.
• W2399742010 cites W2058621664 @default.
• W2399742010 cites W2065293650 @default.
• W2399742010 cites W2065477010 @default.
• W2399742010 cites W2076178766 @default.
• W2399742010 cites W2096198395 @default.
• W2399742010 cites W2098451955 @default.
• W2399742010 cites W2104347254 @default.
• W2399742010 cites W2109080255 @default.
• W2399742010 cites W2111662961 @default.
• W2399742010 cites W2113508099 @default.
• W2399742010 cites W2119540121 @default.
• W2399742010 cites W2126177831 @default.
• W2399742010 cites W2126709309 @default.
• W2399742010 cites W2128208856 @default.
• W2399742010 cites W2128385295 @default.
• W2399742010 cites W2128688922 @default.
• W2399742010 cites W2129360604 @default.
• W2399742010 cites W2129656399 @default.
• W2399742010 cites W2131876608 @default.
• W2399742010 cites W2132157071 @default.
• W2399742010 cites W2135192471 @default.
• W2399742010 cites W2139236349 @default.
• W2399742010 cites W2150371178 @default.
• W2399742010 cites W2152481222 @default.
• W2399742010 cites W2152905269 @default.
• W2399742010 cites W2154149901 @default.
• W2399742010 cites W2159587676 @default.
• W2399742010 cites W2160982674 @default.
• W2399742010 cites W2161821474 @default.
• W2399742010 cites W2166084034 @default.
• W2399742010 cites W2171139285 @default.
• W2399742010 cites W2198093519 @default.
• W2399742010 cites W2207941545 @default.
• W2399742010 cites W2216675461 @default.
• W2399742010 cites W2218718059 @default.
• W2399742010 cites W2234436147 @default.
• W2399742010 cites W2256191967 @default.
• W2399742010 cites W2270997383 @default.
• W2399742010 cites W2301564518 @default.
• W2399742010 cites W2308750957 @default.
• W2399742010 cites W2325170604 @default.
• W2399742010 cites W2336821469 @default.
• W2399742010 cites W2595324731 @default.
• W2399742010 cites W2614546142 @default.
• W2399742010 doi "https://doi.org/10.1001/jamaoncol.2016.0333" @default.
• W2399742010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27196961" @default.
• W2399742010 hasPublicationYear "2016" @default.
• W2399742010 type Work @default.
• W2399742010 sameAs 2399742010 @default.
• W2399742010 citedByCount "29" @default.
• W2399742010 countsByYear W23997420102016 @default.
• W2399742010 countsByYear W23997420102017 @default.
• W2399742010 countsByYear W23997420102018 @default.
• W2399742010 countsByYear W23997420102019 @default.
• W2399742010 countsByYear W23997420102020 @default.
• W2399742010 countsByYear W23997420102021 @default.
• W2399742010 countsByYear W23997420102022 @default.
• W2399742010 countsByYear W23997420102023 @default.
• W2399742010 crossrefType "journal-article" @default.
• W2399742010 hasAuthorship W2399742010A5069070706 @default.
• W2399742010 hasAuthorship W2399742010A5075333926 @default.
• W2399742010 hasConcept C104317684 @default.
• W2399742010 hasConcept C121608353 @default.
• W2399742010 hasConcept C126322002 @default.
• W2399742010 hasConcept C143998085 @default.
• W2399742010 hasConcept C156719811 @default.
• W2399742010 hasConcept C182707283 @default.
• W2399742010 hasConcept C2776256026 @default.
• W2399742010 hasConcept C2777506169 @default.
• W2399742010 hasConcept C2777626846 @default.
• W2399742010 hasConcept C2777930144 @default.
• W2399742010 hasConcept C2778087573 @default.
• W2399742010 hasConcept C2779438470 @default.
• W2399742010 hasConcept C2780580887 @default.
• W2399742010 hasConcept C2780586478 @default.

• next